Balancing Efficacy and High quality of Life in Late-Line RRMM

Panelists talk about how balancing remedy effectiveness with high quality of life in late-line a number of myeloma remedy requires a extremely personalised strategy, with sufferers and physicians collaboratively weighing elements akin to potential for deeper or longer remissions in opposition to toxicity profiles, remedy logistics (inpatient vs. outpatient administration), impression on each day actions, monetary toxicity, caregiver burden and particular person affected person objectives, with many emphasizing that this calculus shifts as sufferers progress by way of remedy strains—typically prioritizing aggressive approaches earlier whereas putting larger emphasis on sustaining performance and significant life experiences in later remedy phases.